Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 21823 30th Dr SE BOTHELL WA 98021-3907 |
Tel: | N/A |
Website: | https://www.seagen.com |
IR: | See website |
Key People | ||
Clay B. Siegall Chairman of the Board, President, Chief Executive Officer | Todd E. Simpson Chief Financial Officer | Jean I. Liu Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary |
Vaughn B. Himes Chief Technical Officer | Roger D. Dansey Chief Medical Officer |
Business Overview |
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1. |
Financial Overview |
For the nine months ended 30 September 2020, SeagenInc revenues increased from $626.9M to $1.57B. Net incometotaled $446.6M vs. loss of $184.5M. Revenues reflectRoyalty revenues increase from $66.2M to $809.9M, Netproduct sales increase of 53% to $706.5M. Net Incomereflects Investment and other income (loss), net increasefrom $2.3M (expense) to $18M (income). |
Employees: | 1,605 as of Dec 31, 2019 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $31,774M as of Sep 30, 2020 |
Annual revenue (TTM): | $1,864M as of Sep 30, 2020 |
EBITDA (TTM): | $439.87M as of Sep 30, 2020 |
Net annual income (TTM): | $472.41M as of Sep 30, 2020 |
Free cash flow (TTM): | $570.68M as of Sep 30, 2020 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 180,306,390 as of Oct 27, 2020 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |